The Business Times
business-time-50

AstraZeneca spins off autoimmune drugs into new biotech company

google-preferred-sourceAdd BT as a preferred source
Published Wed, Feb 28, 2018 · 09:50 PM

London

ASTRAZENECA is spinning off six early-stage experimental drugs into a new US$250 million stand-alone biotech company focused on severe autoimmune diseases.

The spin-off of the three clinical and three pre-clinical biological compounds, announced on Wednesday, is the latest example of the British drugmaker pruning its non-core drug development work to focus on priority areas, notably in cancer.

AstraZeneca

TRENDING NOW

Altitude Xperience argued that the rooftop space in contention was not considered an unused space.

Simba ordered to pay S$700,000 in damages to indoor skydiving operator Altitude Xperience for trespass

The former employees were sued by Envy’s liquidators to claw back payments including commissions, profit-sharing bonuses and referral fees made to them.

Apex court dismisses almost all of the appeals by Envy’s ex-employees over S$38 million of clawbacks

Some industry watchers wonder if Orchard Road can hold its own next to competing retail destinations, both global and local.

What’s wrong with Orchard Road? Experts weigh in on the street’s cachet and its future

The airline said it tapped Bank of China, DBS, HSBC and Standard Chartered for the potential bond sale.

Singapore Airlines plans debut 5-year dim sum bond

Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More